More on ONC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $359.58 |
|
|||
| Open | $351.73 | ||||
| 52 Wk High | $0.35 | ||||
| 52 Wk Low | $0.35 | ||||
| Day High | $360.21 | ||||
| Day Low | $351.41 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 351,276 | ||||
- Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin
- FDA approves BeOne's Tevimbra combo for HER2+ stomach cancer
- BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
- BeOne Medicines renews CLL drug access deal for low-income nations
- BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
- Form 4 BeOne Medicines Ltd. For: Aug 11 Filed by: Lee Chan Henry
- Form 4 BeOne Medicines Ltd. For: Aug 10 Filed by: OYLER JOHN
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- BeOne Medicines (ONC) PT Raised to $405 at Morgan Stanley
- BeOne Medicines (ONC) PT Raised to $454 at TD Cowen
Entities mentioned with ONC
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Canaccord Genuity | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
